Summit Leadership Spotlights
Comfort in Discomfort: Leadership & Innovation Lessons from an Uncommon Alliance
Can an organization be transformed by the alliance it helps create?
Head, Quality Innovation and Engagement
When the Break Dengue alliance was founded in 2012, its partners didn't expect 250,000 followers in a year, multiple global Awards, and a leading share of voice on dengue. An uncommon alliance in healthcare, Break Dengue has opened new avenues to address critical social issues through public-private-people partnerships.
For Sanofi Pasteur, a founding partner of Break Dengue, it has also posed a serious challenge to its own assumptions and operating modes. Celine Schillinger, now Head of Quality Innovation and Engagement at Sanofi Pasteur, will share the mindset and leadership shift this alliance has triggered at the vaccine manufacturer–the starting point for a remarkable corporate culture transformation. Join Celine to learn how Sanofi Pasteur has focused on creating or accelerating their "Alliance Mindset" and the cultural changes required to do so.
Portrayed in Forbes as "driving some of the most award-winning and buzz-worthy employee initiatives at Sanofi Pasteur", Celine directs Innovation and Engagement for Global Quality at Sanofi's vaccine division. A leader in collaborative projects for business and organizational transformation, Celine has been recognized multiple times for her innovative engagement initiatives in the pharma world. Her career spans communications, business operations, HR, marketing, and social engagement across Asia, Europe and now the United States. A TEDx speaker, Celine is passionate about people-centric innovation to modernize the business environment and increase performance. Celine is a Charter Member of the Change Agents Worldwide think tank.
Leveraging Partners to Accelerate Growth and Enter New Markets
President and Chief Executive Officer
Independent Software Vendors (ISVs) are constantly looking to accelerate topline revenue growth. There are a variety of sales models that ISVs can pursue to achieve this: direct sales, indirect sales, or hybrid—a mix of direct and indirect. In the absence of an all-direct sales model, leveraging channels and alliances to drive that growth are often important pieces to the overall revenue strategy. In addition, channel and alliance partners can help open up new markets where establishing a direct sales presence can be difficult and costly. Examining the effectiveness of a hybrid model in a fast-growing ISV is the focus of this Leadership Spotlight from a seasoned sales and executive leader.
Hickey brings a background of software operations, strategy, capital fundraising, and mergers and acquisitions to BeyondTrust, where he is responsible for the company's day-to-day operations. Hickey joined BeyondTrust by way of the company's acquisition of eEye Digital Security, where he served as CEO and chairman. Under Hickey's leadership, eEye experienced significant growth, launched several first-to-market security solutions, and brought the company back to category leadership. Prior to joining eEye, Hickey was CEO of NetPro Computing, where he helped grow the business before concluding its sale to Quest Software. Hickey has also served as the president and CEO of Homebid.com, where he secured funding and eventually sold the business to industry leader HomeStore.com. During his seven years as president and COO at Viasoft Inc., Hickey led the company through a successful initial public offering prior to its sale. He started his IT career at IBM, serving in several key marketing and executive business management roles.
Accelerating Innovation: Partnering Early and Often in the New Era of Cooperation
Chris Haskell, PhD
Head, U.S. Science Hub
Traditionally, startup companies have built their organizations towards IPO as their main exit strategy, partnering only when necessary. A new era brings a greater focus on 'de-risking before big funding," bringing together startup companies, venture capitalists and academia to engage with Big Pharma much earlier in their path towards developing new therapies for patients. Entrepreneurs and companies are defining new collaboration models through creative partnering pathways, while considering the challenges of addressing the ever-changing industry environment. Join this session and learn how Bayer manages this complex ecosystem, while they create value through innovation.
Dr. Christopher Haskell leads Bayer's U.S. Science Hub, based in the company's U.S. Innovation Center located at Mission Bay, San Francisco. Haskell and his group support Bayer's Drug Discovery through developing and managing partnerships with U.S. academic research institutions and emerging life science firms, including the master agreement signed with UCSF in 2011. Haskell is also responsible for the development of the CoLaborator, a biotech incubator space adjacent to the company's U.S. Innovation Center that opened in 2012 in San Francisco. The CoLaborator houses a number of startup life science firms, and has been developed as a vehicle to foster collaboration between Bayer and these emerging innovators.
Haskell is chair of the California Life Sciences Institute, the San Francisco bay area industry trade organization dedicated to fostering entrepreneurship, science education and workforce development. He is also a board member of the California Life Sciences Association.
After his graduate work at the University of California, Davis and a postdoctoral fellowship at The Gladstone Institute in San Francisco, Haskell joined the Immunology group at Berlex Biosciences. Since joining Bayer in 2007, Haskell has served in various scientific leadership roles, including the Acting Head of Applied Research, the unit responsible for hemostasis research and drug development. In late 2009, Haskell was named head of Bayer's newly formed Science Hub.